Overweight and obesity increase the risk for liver cance and long-term oral supplementation with branched-cha liver carcinogenesis in heavier patients with liver cirrho

Hepatology Research

35, 204-14

DOI: 10.1016/j.hepres.2006.04.007

Citation Report

#	Article	IF	Citations
1	Nutritional assessment in liver cirrhosis. Journal of Gastroenterology, 2006, 41, 511-512.	2.3	2
2	The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatology Research, 2007, 37, 510-516.	1.8	55
3	Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatology Research, 2007, 37, 765-770.	1.8	55
4	Restoration of innate host defense responses by oral supplementation of branchedâ€chain amino acids in decompensated cirrhotic patients. Hepatology Research, 2007, 37, 1062-1067.	1.8	41
5	The Benefit of the Supplementation of Perioperative Branched-Chain Amino Acids in Patients with Surgical Management for Hepatocellular Carcinoma: a Preliminary Study. Digestive Diseases and Sciences, 2008, 53, 204-209.	1.1	16
6	Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. Journal of Gastroenterology, 2008, 43, 63-70.	2.3	37
7	Does a late evening meal reduce the risk of hepatocellular carcinoma among patients with chronic hepatitis C?. Hepatology Research, 2008, 38, 860-868.	1.8	2
8	Supplement improves nutrition and stresses caused by examinationâ€associated fasting in patients with liver cirrhosis. Hepatology Research, 2008, 38, 1178-1185.	1.8	6
9	Longâ€term outcome of branchedâ€chain amino acid treatment in patients with liver cirrhosis. Hepatology Research, 2008, 38, S102-6.	1.8	37
10	Obesity Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Clinical Gastroenterology and Hepatology, 2008, 6, 459-464.	2.4	149
11	Hepatocellular Carcinoma in Keio Affiliated Hospitals â€" Diagnosis, Treatment, and Prognosis of this Disease â€". Keio Journal of Medicine, 2009, 58, 161-175.	0.5	9
12	Supplementation with Branched-chain Amino Acids Inhibits Azoxymethane-induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Mice. Clinical Cancer Research, 2009, 15, 3068-3075.	3.2	60
13	Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology, 2009, 50, 1936-1945.	3.6	56
14	A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: Validation using prognostic markers for pre-liver transplant status. Liver Transplantation, 2009, 15, 790-797.	1.3	50
15	Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. Journal of Gastroenterology, 2009, 44, 483-491.	2.3	60
16	Diabetes pattern on the 75â€fg oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver International, 2009, 29, 1194-1201.	1.9	39
17	1. Treatment of Hepatic Cirrhosis.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 2223-2229.	0.0	0
18	Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. Journal of Gastroenterology, 2010, 45, 443-450.	2.3	33

#	Article	IF	Citations
19	Dietary supplementation with branchedâ€chain amino acids suppresses diethylnitrosamineâ€induced liver tumorigenesis in obese and diabetic C57BL/KsJâ€db/db mice. Cancer Science, 2010, 101, 460-467.	1.7	82
20	Effects of branchedâ€chain amino acidâ€enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: A oneâ€year prospective trial. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1550-1555.	1.4	44
21	Importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization. World Journal of Gastroenterology, 2010, 16, 1943.	1.4	55
22	Isoleucine Prevents the Accumulation of Tissue Triglycerides and Upregulates the Expression of PPARÎ± and Uncoupling Protein in Diet-Induced Obese Mice. Journal of Nutrition, 2010, 140, 496-500.	1.3	95
23	Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatology Research, 2010, 40, 550-554.	1.8	17
24	Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virusâ€positive patients: A prospective, case series study. Hepatology Research, 2010, 40, 376-382.	1.8	43
25	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatology Research, 2010, 40, 1-7.	1.8	78
26	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatology Research, 2010, 40, 8-13.	1.8	92
27	Chapter 2: Diagnosis and surveillance. Hepatology Research, 2010, 40, 16-47.	1.8	15
28	Effects of late evening snack on diurnal plasma glucose profile in patients with chronic viral liver disease. Hepatology Research, 2010, 40, 887-893.	1.8	7
29	Effects of late evening snack including branchedâ€chain amino acid on the function of hepatic parenchymal cells in patients with liver cirrhosis. Hepatology Research, 2011, 41, 417-422.	1.8	18
30	Sustained viral response (SVR) in type C liver cirrhosis patients undergoing peginterferon Î±-2b/ribavirin combination therapy after partial splenic embolization. Acta Hepatologica Japonica, 2011, 52, 26-35.	0.0	0
31	Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. Journal of Clinical Biochemistry and Nutrition, 2011, 49, 153-158.	0.6	35
32	Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/dbobese mice. BMC Cancer, 2011, 11, 281.	1.1	45
33	Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Molecular Nutrition and Food Research, 2011, 55, 832-843.	1.5	105
34	Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology, 2011, 54, 1063-1070.	3.6	276
35	Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. International Journal of Cancer, 2011, 129, 2226-2235.	2.3	70
36	Preventive Effects of (â^)-Epigallocatechin Gallate on Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-db/db Mice. Cancer Prevention Research, 2011, 4, 396-403.	0.7	76

#	Article	IF	Citations
37	Oral Branched-Chain Amino Acid Granules Reduce the Incidence of Hepatocellular Carcinoma and Improve Event-Free Survival in Patients with Liver Cirrhosis. Digestive Diseases, 2011, 29, 326-332.	0.8	57
38	Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-Î± for prevention of liver carcinogenesis. Journal of Carcinogenesis, 2012, 11, 11.	2.5	23
39	Nutraceutical Approach for Preventing Obesity-Related Colorectal and Liver Carcinogenesis. International Journal of Molecular Sciences, 2012, 13, 579-595.	1.8	37
40	Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake. Gastroenterology Research and Practice, 2012, 2012, 1-8.	0.7	21
41	Clofibrate-Induced Reduction of Plasma Branched-Chain Amino Acid Concentrations Impairs Glucose Tolerance in Rats. Journal of Parenteral and Enteral Nutrition, 2012, 36, 337-343.	1.3	20
42	Valine, a Branched-Chain Amino Acid, Reduced HCV Viral Load and Led to Eradication of HCV by Interferon Therapy in a Decompensated Cirrhotic Patient. Case Reports in Gastroenterology, 2012, 6, 660-667.	0.3	11
43	Risk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFNÎ±-2a. Digestive Diseases, 2012, 30, 561-567.	0.8	2
44	Hepatocellular carcinoma in nonâ€alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatology Research, 2012, 42, 1-14.	1.8	106
45	Long-term treatment with l-isoleucine or l-leucine in AIN-93G diet has promoting effects on rat bladder carcinogenesis. Food and Chemical Toxicology, 2012, 50, 3934-3940.	1.8	14
46	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. Journal of Hepatology, 2012, 56, 103-108.	1.8	142
47	Branchedâ€chain amino acid deficiency stabilizes insulinâ€induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells. Journal of Cellular Biochemistry, 2012, 113, 3113-3121.	1.2	23
48	Nutritional support for liver disease. The Cochrane Library, 2012, , CD008344.	1.5	79
49	Combination of acyclic retinoid with branchedâ€chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice. Hepatology Research, 2012, 42, 1241-1247.	1.8	4
50	Early administration of branched-chain amino acid granules. World Journal of Gastroenterology, 2012, 18, 4486.	1.4	13
51	Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Management and Research, 2012, 4, 423.	0.9	7
52	Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatology Research, 2012, 42, 621-626.	1.8	37
53	Branchedâ€chain amino acids prevent insulinâ€induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2â€dependent mechanisms. Journal of Cellular Physiology, 2012, 227, 2097-2105.	2.0	57
54	Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Seminars in Immunopathology, 2013, 35, 191-202.	2.8	48

#	Article	IF	Citations
55	Oral supplementation of branched-chain amino acids reduces early recurrence after hepatic resection in patients with hepatocellular carcinoma: a prospective study. Surgery Today, 2013, 43, 720-726.	0.7	66
56	Nutritional assessment and treatment of patients with liver cirrhosis. Nutrition, 2013, 29, 1279-1285.	1.1	53
57	Long-term Branched Chain Amino Acid Supplementation Ameliorates Diethylnitrosamine-induced Liver Glutathione S-transferase-p Positivity in Zucker Fatty Rats. Journal of Clinical and Experimental Hepatology, 2013, 3, 192-197.	0.4	4
58	Effects of Oral Branchedâ€Chain Amino Acids on Hepatic Encephalopathy and Outcome in Patients With Liver Cirrhosis. Nutrition in Clinical Practice, 2013, 28, 580-588.	1.1	58
59	Diuretics aggravate zinc deficiency in patients with liver cirrhosis by increasing zinc excretion in urine. Hepatology Research, 2013, 43, 365-373.	1.8	33
60	A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids. Metabolomics, 2013, 9, 818-827.	1.4	212
61	DNA microarray analysis identified molecular pathways mediating the effects of supplementation of branchedâ€chain amino acids on CCl₄â€induced cirrhosis in rats. Molecular Nutrition and Food Research, 2013, 57, 291-306.	1.5	14
62	Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncology Reports, 2013, 30, 545-552.	1.2	17
63	Incidence, Mortality, and Predictive Factors of Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Gastroenterology Research and Practice, 2013, 2013, 1-8.	0.7	11
64	Effects of branchedâ€chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis. Hepatology Research, 2013, 43, 459-466.	1.8	11
65	Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007â€“2011. Hepatology Research, 2013, 43, 106-112.	1.8	63
66	Body Mass Index and Weight Change During Adulthood Are Associated With Increased Mortality From Liver Cancer: The JACC Study. Journal of Epidemiology, 2013, 23, 219-226.	1.1	13
67	The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. Journal of Clinical Gastroenterology, 2013, 47, 359-366.	1.1	36
68	Branched-chain amino acids in liver diseases. World Journal of Gastroenterology, 2013, 19, 7620.	1.4	152
69	Branched-Chain Amino Acid Supplementation Reduces Oxidative Stress and Prolongs Survival in Rats with Advanced Liver Cirrhosis. PLoS ONE, 2013, 8, e70309.	1.1	50
70	Branched-Chain Amino Acids Ameliorate Fibrosis and Suppress Tumor Growth in a Rat Model of Hepatocellular Carcinoma with Liver Cirrhosis. PLoS ONE, 2013, 8, e77899.	1.1	39
71	Branched-Chain Amino Acids Enhance Premature Senescence through Mammalian Target of Rapamycin Complex I-Mediated Upregulation of p21 Protein. PLoS ONE, 2013, 8, e80411.	1.1	32
72	Insulin resistance as early sign of hepatic dysfunction in liver cirrhosis. Journal of Medical Investigation, 2014, 61, 180-189.	0.2	18

#	Article	IF	Citations
73	Impact of Serum Chemerin Levels on Liver Functional Reserves and Platelet Counts in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2014, 15, 11294-11306.	1.8	26
74	Clinical significance of therapy using branchedâ€chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatology Research, 2014, 44, 149-158.	1.8	34
75	Oral supplementation with branchedâ€chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis <scp>C</scp>â€related cirrhosis: A propensity score analysis. Hepatology Research, 2014, 44, 288-295.	1.8	10
76	Serum albumin level is a notable profiling factor for nonâ€<scp>B</scp>, nonâ€<scp>C</scp> hepatitis virusâ€related hepatocellular carcinoma: A dataâ€mining analysis. Hepatology Research, 2014, 44, 837-845.	1.8	26
77	Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma. BMC Cancer, 2014, 14, 907.	1.1	21
78	Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: Chemoprevention of hepatocellular carcinoma using acyclic retinoid and branchedâ€chain amino acids. Molecular Nutrition and Food Research, 2014, 58, 124-135.	1.5	8
79	Branched-chain amino acids in metabolic signalling and insulin resistance. Nature Reviews Endocrinology, 2014, 10, 723-736.	4.3	1,006
80	Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. Journal of Diabetes and Metabolic Disorders, 2014, 13, 57.	0.8	25
81	Effect of zinc on liver cirrhosis with hyperammonemia: A preliminary randomized, placebo-controlled double-blind trial. Nutrition, 2014, 30, 1409-1414.	1.1	67
82	Branched-Chain Amino Acids Prevent Hepatocarcinogenesis and Prolong Survival of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1012-1018.e1.	2.4	84
83	Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutrition Journal, 2015, 14, 67.	1.5	37
84	Impact of the branchedâ€chain amino acid to tyrosine ratio and branchedâ€chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1412-1419.	1.4	24
85	Changing epidemiology of hepatocellular carcinoma in Asia. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 919-928.	1.0	121
86	Chemopreventive Potential of Green Tea Catechins in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2015, 16, 6124-6139.	1.8	42
87	Effect of branched-chain amino acid supplementation on functional liver regeneration in patients undergoing portal vein embolization and sequential hepatectomy: a randomized controlled trial. Journal of Gastroenterology, 2015, 50, 1197-1205.	2.3	38
88	Prognostic Impact of Visceral Fat Amount and Branched-Chain Amino Acids (BCAA) in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 1041-1047.	0.7	21
89	Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection. Annals of Surgical Oncology, 2015, 22, 1034-1040.	0.7	26
90	Branchedâ€chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyproteinâ€expressing mice. Liver International, 2015, 35, 1303-1314.	1.9	23

#	Article	IF	Citations
91	Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment. Journal of Gastroenterology, 2015, 50, 109-118.	2.3	15
92	Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan - a cohort study. Oncotarget, 2016, 7, 22948-22959.	0.8	35
93	Impact of branchedâ€chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort study. Hepatology Research, 2016, 46, 1002-1010.	1.8	21
94	Role of Nutrition and Muscle in Cirrhosis. Current Treatment Options in Gastroenterology, 2016, 14, 257-273.	0.3	40
95	Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment. Tumor Biology, 2016, 37, 14363-14380.	0.8	21
96	Leucine and Mammalian Target of Rapamycinâ€"Dependent Activation of Muscle Protein Synthesis in Aging. Journal of Nutrition, 2016, 146, 2616S-2624S.	1.3	42
97	Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study. Journal of Nippon Medical School, 2016, 83, 248-256.	0.3	14
98	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. Journal of Hepatology, 2016, 65, 363-368.	1.8	68
99	Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of Gastroenterology, 2016, 51, 629-650.	2.3	253
100	Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism: Clinical and Experimental, 2017, 69, 177-187.	1.5	80
101	Liver Transplantation and Bariatric Surgery. Clinics in Liver Disease, 2017, 21, 215-230.	1.0	21
102	Nutrition and the transplant candidate. Liver Transplantation, 2017, 23, 1451-1464.	1.3	46
103	Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1416-1423.	0.8	113
104	Nutrition for the Patient with Advanced Liver Disease. Current Hepatology Reports, 2017, 16, 205-211.	0.4	0
105	Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease. Medicine (United States), 2017, 96, e6580.	0.4	45
106	Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial. Nutrition, 2017, 33, 20-27.	1.1	37
107	Branchedâ€chain amino acids differently modulate catabolic and anabolic states in mammals: a pharmacological point of view. British Journal of Pharmacology, 2017, 174, 1366-1377.	2.7	107
108	Does Nutrition Matter in Liver Disease?. , 2017, , 743-759.		2

#	Article	IF	Citations
109	Nutritional Status in Liver Cirrhosis. , 2017, , .		1
110	Antiangiogenic Therapy for Hepatocellular Carcinoma. , 2017, , .		0
111	Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World Journal of Clinical Oncology, 2017, 8, 429-436.	0.9	73
112	The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study. Journal of Gastroenterology, 2018, 53, 978-988.	2.3	17
113	The Value of the Câ€Reactive Proteinâ€toâ€Albumin Ratio is Useful for Predicting Survival of Patients with Childâ€“Pugh Class A Undergoing Liver Resection for Hepatocellular Carcinoma. World Journal of Surgery, 2018, 42, 2218-2226.	0.8	21
114	Metabonomics of <scp>d</scp>-glucaro-1,4-lactone in preventing diethylnitrosamine-induced liver cancer in rats. Pharmaceutical Biology, 2018, 56, 643-648.	1.3	16
115	Is the Response of Tumours Dependent on the Dietary Input of Some Amino Acids or Ratios among Essential and Non-Essential Amino Acids? All That Glitters Is Not Gold. International Journal of Molecular Sciences, 2018, 19, 3631.	1.8	3
116	Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell, 2018, 175, 947-961.e17.	13.5	517
117	Secondary Unconjugated Bile Acids Induce Hepatic Stellate Cell Activation. International Journal of Molecular Sciences, 2018, 19, 3043.	1.8	18
118	Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome. Metabolomics, 2018, 14, 90.	1.4	10
119	Obesity and recurrenceâ€free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C. Annals of Gastroenterological Surgery, 2018, 2, 319-326.	1.2	10
120	Nutrition is often ignored in management of chronic liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1127-1128.	1.4	1
121	Obesity and Hepatocarcinogenesis. , 2019, , 87-102.		0
122	Late evening snacks with branched-chain amino acids improve the Fischer ratio with patients liver cirrhosis at fasting in the next morning. Clinical Nutrition ESPEN, 2019, 30, 138-144.	0.5	14
123	Prevalence of diabetes in liver cirrhosis: A systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2019, 35, e3157.	1.7	42
124	Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios. Nutrition and Cancer, 2019, 71, 1132-1141.	0.9	11
125	Effects of Zinc Acetate on Serum Zinc Concentrations in Chronic Liver Diseases: a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial and a Dose Adjustment Trial. Biological Trace Element Research, 2020, 195, 71-81.	1.9	14
126	Anti-obesity effects of Î±-amylase inhibitor enriched-extract from white common beans (<i>Phaseolus) Tj ETQq1 1 0.784314 rgBT /Ov obese rats. Food and Function, 2020, 11, 1624-1634.	2.1	41

#	Article	IF	Citations
127	Zinc and protein metabolism in chronic liver diseases. Nutrition Research, 2020, 74, 1-9.	1.3	48
128	Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. Scientific Reports, 2020, 10, 18768.	1.6	31
129	Dietary Approaches to Cancer Therapy. Cancer Cell, 2020, 37, 767-785.	7.7	105
130	Diet and liver cancer risk: a narrative review of epidemiological evidence. British Journal of Nutrition, 2020, 124, 330-340.	1.2	95
131	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opinion on Pharmacotherapy, 2020, 21, 953-967.	0.9	28
132	A Comprehensive Review Evaluating the Impact of Protein Source (Vegetarian vs. Meat Based) in Hepatic Encephalopathy. Nutrients, 2021, 13, 370.	1.7	7
133	A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity. Communications Biology, 2021, 4, 217.	2.0	21
134	Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. International Journal of Molecular Sciences, 2021, 22, 1917.	1.8	25
135	Malnutrition in Patients with Liver Cirrhosis. Nutrients, 2021, 13, 540.	1.7	57
136	Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment. Cancers, 2021, 13, 1542.	1.7	9
137	Obesity and Liver Cancer in Japan: A Comprehensive Review. Anticancer Research, 2021, 41, 2227-2237.	0.5	5
138	A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Scientific Reports, 2021, 11, 11861.	1.6	10
139	Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. Hpb, 2022, 24, 101-115.	0.1	23
140	The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 516.	1.7	15
141	Assessment of Nutritional Status of Patients with Chronic Hepatitis C and HCV-Related Cirrhosis in the Compensated Stage. American Journal of Internal Medicine, 2016, 4, 24.	0.1	1
142	Branched Chain Amino Acid Suppresses Hepatocellular Cancer Stem Cells through the Activation of Mammalian Target of Rapamycin. PLoS ONE, 2013, 8, e82346.	1.1	34
143	Metformin Suppresses Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-+Leprdb/+Leprdb Mice. PLoS ONE, 2015, 10, e0124081.	1.1	22
144	Feasibility Study of NMR Based Serum Metabolomic Profiling to Animal Health Monitoring: A Case Study on Iron Storage Disease in Captive Sumatran Rhinoceros (Dicerorhinus sumatrensis). PLoS ONE, 2016, 11, e0156318.	1.1	10

#	Article	IF	Citations
145	The Prevalence and Implication of Zinc Deficiency in Patients With Chronic Liver Disease. Journal of Clinical Medicine Research, 2018, 10, 437-444.	0.6	47
146	Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model. Oncotarget, 2017, 8, 18191-18205.	0.8	59
147	Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget, 2017, 8, 58353-58363.	0.8	47
148	Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment. Oncotarget, 2018, 9, 14058-14067.	0.8	15
149	Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice. Oncotarget, 2016, 7, 10448-10458.	0.8	22
150	Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World Journal of Gastroenterology, 2012, 18, 4071.	1.4	115
151	Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. World Journal of Gastroenterology, 2012, 18, 5759.	1.4	32
152	Impairment of innate immune responses in cirrhotic patients and treatment by branched-chain amino acids. World Journal of Gastroenterology, 2014, 20, 7298.	1.4	24
153	Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities. World Journal of Gastroenterology, 2014, 20, 8939-46.	1.4	14
154	Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World Journal of Gastroenterology, 2016, 22, 394.	1.4	12
155	Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World Journal of Gastroenterology, 2016, 22, 7252.	1.4	15
156	Nutrition and metabolism in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2013, 2, 89-96.	0.7	12
157	Effect of zinc supplementation in patients with type C liver cirrhosis. Open Journal of Gastroenterology, 2011, 01, 28-34.	0.1	10
158	Treating morbid obesity in cirrhosis: A quest of holy grail. World Journal of Hepatology, 2015, 7, 2819.	0.8	17
159	Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian Journal of Hepato-gastroenterology, 2019, 9, 27-33.	0.1	23
160	Comparison of measured and predicted energy expenditure in patients with liver cirrhosis. Asia Pacific Journal of Clinical Nutrition, 2014, 23, 197-204.	0.3	13
161	Insulin resistance as early sign of hepatic dysfunction in liver cirrhosis . Journal of Medical Investigation, 2000, 40, 180-189.	0.2	0
162	The effect of hepatic steatosis on Peginterferon alfa-2b and Ribavirin combination therapy for chronic hepatitis C. Acta Hepatologica Japonica, 2008, 49, 183-191.	0.0	2

#	Article	IF	Citations
163	Effects of Branched-chain Amino Acid Supplementation in Rats Fed a Vitamin B₆-deficient Diet. Nihon EiyÅ•ShokuryÅ•Gakkai Shi = Nippon EiyÅ•ShokuryÅ•Gakkaishi = Journal of Japanese Society of Nutrition and Food Science, 2012, 65, 65-73.	0.2	1
164	æ„éŠæŠ•ä¸Žã«ã‚ˆã‚‹ç™Œå†…å¢—æ®–æ©Ÿæ§‹ã®å¯¾¼¡. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2013, 47,	0.1	0
165	é«˜é½¢è€…ã‚„å‚·ç—…è€…ã«ãŠã‘ã‚‹è¡“æœŸæ„„éŠç®¡ç†ã®å•é¡Œç‚¹. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2014, 4	0.1	0
166	Identification of Branched Chain Amino Acids; Underlying Molecular Pathways Using Transcriptomic Analysis: Application to Cirrhosis. , 2015, , 141-157.		0
167	Branched-chain amino acid metabolism and insulin resistance. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2015, 49, 177-182.	0.1	0
168	Metabolic Syndrome and the Liver. , 2016, , 149-177.		0
169	Three step primary liver cancer prevention program utilizing dynamic tumor marker combination assay in high-risk patients with chronic hepatitis. MOJ Current Research & Reviews, 2018, 1, 114-117.	0.1	0
170	Nutrition in Liver Cirrhosis. , 2019, , 69-77.		0
172	Bariatric Surgery and Liver Transplantation. Gastroenterology and Hepatology, 2017, 13, 170-175.	0.2	2
173	ANXA2, PRKCE, and OXT are critical differentially genes in Nonalcoholic fatty liver disease. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 131-137.	0.6	6
174	Favorable and harmful effects of branched-chain amino acid administration in patients with liver cirrhosis: effects on hepatic encephalopathy and ammonia metabolism. Acta Hepatologica Japonica, 2022, 63, 1-8.	0.0	0
175	Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clinical and Molecular Hepatology, 2022, 28, 425-472.	4.5	14
176	The Complex of Phycobiliproteins, Fucoxanthin, and Krill Oil Ameliorates Obesity through Modulation of Lipid Metabolism and Antioxidants in Obese Rats. Nutrients, 2022, 14, 4815.	1.7	1
177	Recent Progress of Nutritional Management for Liver Cirrhosis. Journal of Nutritional Science and Vitaminology, 2022, 68, S73-S75.	0.2	0
178	Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2023, 24, 210.	1.8	9
179	VII. Nutrition and Exercise Therapies for Liver Cirrhosis. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 50-57.	0.0	0